DRD1 is a G protein-coupled dopamine receptor that mediates cellular responses through adenylyl cyclase activation and cyclic adenosine monophosphate (cAMP) signaling 1. Structurally, DRD1 recognizes dopamine through a polar interaction network and can form heterotetramers with DRD3 to regulate beta-arrestin recruitment and locomotor activity 2. Beyond classical neurotransmission, DRD1 plays immunomodulatory roles: dopamine suppresses group 2 innate lymphoid cell responses in allergic airway inflammation through DRD1-dependent inhibition of mitochondrial oxidative phosphorylation 3, and DRD1 signaling prevents NLRP3 inflammasome activation via cAMP-mediated ubiquitination and degradation, thereby reducing neuroinflammation and systemic inflammation 1. Clinically, DRD1 gene polymorphisms (particularly rs4532) are associated with hypertension risk in ethnicity-specific patterns 4 and with chr5 obstructive pulmonary disease subtypes featuring mucin hypersecretion and accelerated lung function decline 5. DRD1 agonists show promise as antifibrotic agents through YAP/TAZ pathway inhibition in pulmonary fibrosis 6. Additionally, DRD1 variants associate with alcohol dependence in some populations 7 and represent candidate genes in attention-deficit/hyperactivity disorder pathogenesis 8.